Todos Medical Enters into Coronavirus Nucleic Acid
Post# of 30028
(Total Views: 451)
Posted On: 03/17/2020 12:17:02 PM
Todos Medical Enters into Coronavirus Nucleic Acid Buccal Testing Kit Distribution Agreement with 3D BioMed
3D BioMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial
Nucleic Acid test performed on proprietary automated platform to increase throughput
CE Mark and Chinese FDA approval have been received; 3D BioMed in discussions with US FDA
Technology was deployed in Wuhan, China with over 100,000 tests completed
Combination coronavirus and influenza A/B testing novel among PCR approaches
REHOVOT, Israel and New York, NY, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3D Biomedicine Science & Technology Co., a China-based cancer precision medicine company, for distribution in the US and Israel of 3D BioMed’s 3DMed 2019-nCoV Detection Kit (COVID), 3DMed 2019-nCoV & Flu A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). 3D BioMed’s COVID, COVID/Flu and 3D Machine have received approval from the Chinese FDA and have received a CE Mark in Europe. 3D BioMed is currently engaged in discussions with the FDA regarding approval of its products.
“I am very pleased to help Todos and 3D BioMed bring this technology forward for commercial launch in the US under CLIA, and help support FDA approval for 3D BioMed’s suite of products here in the United States as quickly as possible,” said Jorge Leon, PhD, Chief Medical Advisor to Todos. “The main differentiation in the 3D BioMed offering vs. other nucleic acid PCR-based testing is the influenza A and B tests combined with coronavirus testing. This is a clinically meaningful combination because of the extended flu season in the United States that will create additional doubt among healthcare providers regarding the cause of symptoms for patients. The fact that this will be available in one testing paradigm seems to be novel in the United States.”
Concurrent with this announcement, Todos and Provista Diagnostics, Inc. have agreed to use Provista’s lab in Alpharetta, Georgia to conduct the CLIA validation required to launch the test in the United States. All inquiries should be directed via email to covidtesting@provistadx.com. Rao Mulpuri, PhD, MBA Chief Operating Officer of Provista, commented, “Todos Medical and Provista Diagnostics will work together to complete the validation and make the product available to healthcare providers in a timely manner.”
3D BioMed has shipped materials to the Provista lab in Georgia in order to support the validation being conducted over the coming weeks.
“PCR is the current gold standard for diagnosing novel coronavirus in the United States and abroad,” said Gerald Commissiong, President & CEO of Todos. “We believe 3D BioMed’s 3D Machine and kits provide some of the best results in the market because of the engineering applied in establishing the automation that reduces variability and human error in the lab, while significantly increasing throughput. We intend to work expeditiously to validate this technology at Provista, so that we can come online in the US and add additional critically needed testing capacity to the nation’s infrastructure. We will be targeting nursing homes, senior care centers, and ensuring that governments have access to our testing capabilities for their constituencies.”
https://investor.todosmedical.com/news-events...cid-buccal
3D BioMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial
Nucleic Acid test performed on proprietary automated platform to increase throughput
CE Mark and Chinese FDA approval have been received; 3D BioMed in discussions with US FDA
Technology was deployed in Wuhan, China with over 100,000 tests completed
Combination coronavirus and influenza A/B testing novel among PCR approaches
REHOVOT, Israel and New York, NY, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3D Biomedicine Science & Technology Co., a China-based cancer precision medicine company, for distribution in the US and Israel of 3D BioMed’s 3DMed 2019-nCoV Detection Kit (COVID), 3DMed 2019-nCoV & Flu A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). 3D BioMed’s COVID, COVID/Flu and 3D Machine have received approval from the Chinese FDA and have received a CE Mark in Europe. 3D BioMed is currently engaged in discussions with the FDA regarding approval of its products.
“I am very pleased to help Todos and 3D BioMed bring this technology forward for commercial launch in the US under CLIA, and help support FDA approval for 3D BioMed’s suite of products here in the United States as quickly as possible,” said Jorge Leon, PhD, Chief Medical Advisor to Todos. “The main differentiation in the 3D BioMed offering vs. other nucleic acid PCR-based testing is the influenza A and B tests combined with coronavirus testing. This is a clinically meaningful combination because of the extended flu season in the United States that will create additional doubt among healthcare providers regarding the cause of symptoms for patients. The fact that this will be available in one testing paradigm seems to be novel in the United States.”
Concurrent with this announcement, Todos and Provista Diagnostics, Inc. have agreed to use Provista’s lab in Alpharetta, Georgia to conduct the CLIA validation required to launch the test in the United States. All inquiries should be directed via email to covidtesting@provistadx.com. Rao Mulpuri, PhD, MBA Chief Operating Officer of Provista, commented, “Todos Medical and Provista Diagnostics will work together to complete the validation and make the product available to healthcare providers in a timely manner.”
3D BioMed has shipped materials to the Provista lab in Georgia in order to support the validation being conducted over the coming weeks.
“PCR is the current gold standard for diagnosing novel coronavirus in the United States and abroad,” said Gerald Commissiong, President & CEO of Todos. “We believe 3D BioMed’s 3D Machine and kits provide some of the best results in the market because of the engineering applied in establishing the automation that reduces variability and human error in the lab, while significantly increasing throughput. We intend to work expeditiously to validate this technology at Provista, so that we can come online in the US and add additional critically needed testing capacity to the nation’s infrastructure. We will be targeting nursing homes, senior care centers, and ensuring that governments have access to our testing capabilities for their constituencies.”
https://investor.todosmedical.com/news-events...cid-buccal
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼